Helicobacter pylori Eradication, Gastric Cancer Prevention, and Bismuth-Based Therapies
This community focuses on the clinical management of Helicobacter pylori infection, specifically developing and evaluating antibiotic regimens to eradicate the bacterium and reduce the risk of gastric cancer.
The research centers on optimizing treatment protocols, with a strong emphasis on bismuth quadruple therapy, dual therapies, and potassium-competitive acid blockers. A significant portion of the work involves randomized controlled trials and systematic meta-analyses to assess the efficacy and safety of these regimens against antibiotic resistance. The community also investigates the role of H. pylori in gastric carcinogenesis and compares eradication strategies across different populations. While the primary focus is clinical gastroenterology, the inclusion of bismuth compounds also drives a parallel stream of inorganic chemistry research, specifically the synthesis, crystal structure characterization, and biological activity of bismuth(III) and bismuth(V) complexes.
The largest share of the community's output is found in bismuth research, representing 6.4% of all bismuth research, and 5,621 papers here. This element leads both in share and raw count.
The community comprises 15,598 papers, publishing most frequently in Gastroenterology, Helicobacter, and Gut.
Recent work continues to refine eradication guidelines, including the Taipei Global Consensus II and updated Japanese guidelines, while exploring novel delivery systems like nanoemulsions and evaluating the efficacy of newer acid-suppressing agents such as vonoprazan and tegoprazan in dual therapy regimens.